Alnylam Pharmaceuticals Stock Alpha and Beta Analysis
| ALNY Stock | USD 246.80 1.99 0.80% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Alnylam Pharmaceuticals. It also helps investors analyze the systematic and unsystematic risks associated with investing in Alnylam Pharmaceuticals over a specified time horizon. Remember, high Alnylam Pharmaceuticals' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Alnylam Pharmaceuticals' market risk premium analysis include:
Beta 1.27 | Alpha (0.29) | Risk 2.48 | Sharpe Ratio (0.04) | Expected Return (0.10) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Alnylam |
Alnylam Pharmaceuticals Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Alnylam Pharmaceuticals market risk premium is the additional return an investor will receive from holding Alnylam Pharmaceuticals long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Alnylam Pharmaceuticals. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Alnylam Pharmaceuticals' performance over market.| α | -0.29 | β | 1.27 |
Alnylam Pharmaceuticals expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Alnylam Pharmaceuticals' Buy-and-hold return. Our buy-and-hold chart shows how Alnylam Pharmaceuticals performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Alnylam Pharmaceuticals Market Price Analysis
Market price analysis indicators help investors to evaluate how Alnylam Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Alnylam Pharmaceuticals shares will generate the highest return on investment. By understating and applying Alnylam Pharmaceuticals stock market price indicators, traders can identify Alnylam Pharmaceuticals position entry and exit signals to maximize returns.
Alnylam Pharmaceuticals Return and Market Media
The median price of Alnylam Pharmaceuticals for the period between Sat, Aug 24, 2024 and Fri, Nov 22, 2024 is 272.73 with a coefficient of variation of 5.48. The daily time series for the period is distributed with a sample standard deviation of 14.88, arithmetic mean of 271.57, and mean deviation of 10.96. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Disposition of 17560 shares by Pyott David E I of Alnylam Pharmaceuticals at 88.95 subject to Rule 16b-3 | 10/18/2024 |
2 | Alnylam Pharmaceuticals Expected to Beat Earnings Estimates Should You Buy | 10/24/2024 |
3 | Alnylam Pharmaceuticals Third Quarter 2024 Earnings EPS Beats Expectations, Revenues Lag | 11/01/2024 |
4 | Wellington Management Group LLPs Strategic Reduction in Alnylam Pharmaceuticals Inc | 11/08/2024 |
5 | High Growth Tech And 2 Other Promising Stocks with Potential Growth | 11/11/2024 |
6 | Alnylam stock downgraded to underperform over long-term value concerns | 11/12/2024 |
7 | High Growth Tech Stocks Featuring ALSO Holding And 2 More | 11/14/2024 |
8 | Mass. life science stocks plunge on prospect of RFK Jr. as HHS head | 11/15/2024 |
9 | Alnylam shares hold Buy rating as TD Cowen notes sustained efficacy in interim Phase 1b results | 11/18/2024 |
10 | Alnylam stock holds price target and buy rating on promising drug data | 11/19/2024 |
11 | Paragon Therapeutics Appoints Susanna High as Chief Executive Officer | 11/21/2024 |
About Alnylam Pharmaceuticals Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Alnylam or other stocks. Alpha measures the amount that position in Alnylam Pharmaceuticals has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2021 | 2022 | 2023 | 2024 (projected) | Payables Turnover | 1.91 | 1.72 | 5.59 | 5.87 | Days Of Inventory On Hand | 319.57 | 278.83 | 104.82 | 99.58 |
Alnylam Pharmaceuticals Upcoming Company Events
As portrayed in its financial statements, the presentation of Alnylam Pharmaceuticals' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Alnylam Pharmaceuticals' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Alnylam Pharmaceuticals' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Alnylam Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Alnylam Pharmaceuticals' management manipulating its earnings.
| 22nd of February 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 22nd of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Alnylam Pharmaceuticals
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Alnylam Stock Analysis
When running Alnylam Pharmaceuticals' price analysis, check to measure Alnylam Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alnylam Pharmaceuticals is operating at the current time. Most of Alnylam Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Alnylam Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alnylam Pharmaceuticals' price. Additionally, you may evaluate how the addition of Alnylam Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.